Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC

The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.

Related Keywords

Canada ,Chicago ,Illinois ,United States ,Montreal ,Quebec ,Fred Saad ,Prostate Cancer Working Group ,Oncologic Drugs Advisory Committee ,Centre Hospitalier ,Astrazeneca ,Prescription Drug User Fee Act ,Aua Annual Meeting ,News ,Conference ,Lynparza ,Olaparib ,Abiraterone Acetate ,Zytiga ,Nct03732820 ,Propel Trial ,Metastatic Castration Resistant Prostate Cancer ,Nmcrpc ,